原因不明反復流産女性における抗HSP60抗体と抗HSP70抗体の上昇 by Matsuda, Miwa
R ecurrent pregnancy loss (RPL) is defined as the occurrence of more than two failed clinical preg-
nancies [1].  Two consecutive miscarriages occur in 
< 5% of women,  and three or more consecutive miscar-
riages occur in approx.  1% [2].  The causes of RPL are 
diverse and include uterine malformations,  immune 
disorders such as antiphospholipid antibody syndrome 
(APS) and systemic lupus erythematosus (SLE),  endo-
crine disorders such as thyroid dysfunction and diabe-
tes,  coagulopathies,  infection,  and parental or fetal 
chromosomal abnormalities.  However,  approx.  50% of 
RPL cases remain unexplained [3].  Although it is 
assumed that abnormal embryonic karyotype is 
involved in many unexplained RPL cases [4],  the causes 
of the unexplained RPL remain to be established.
We reported uterine circulatory failure with vascular 
dysfunction in women with RPL [5-8].  Vascular dys-
function in the uterine arteries is thought to play an 
important role in causing miscarriages,  fetal growth 
restriction,  and fetal death [8].  The evidence that uter-
ine artery vascular resistance at the early stage of preg-
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Vascular dysfunction has been reported in women with recurrent pregnancy loss (RPL).  We investigated the 
severity of vascular dysfunction in non-pregnant women with RPL and its correlation with anti-heat shock pro-
tein (HSP) antibodies that are known to induce arteriosclerosis.  We measured the serum anti-HSP60 antibod-
ies,  anti-HSP70 antibodies,  and anti-phospholipid antibodies (APA) in 68 women with RPL and 29 healthy 
controls.  Among the women with RPL,  14 had a diagnosis of antiphospholipid syndrome (APS),  and in the 
remaining 54,  the causes for RPL were unexplained.  Compared to the controls,  the brachial-ankle pulse wave 
velocity (baPWV),  carotid augmentation index (cAI),  and uterine artery pulsatility index (PI) were all signifi-
cantly higher in the women with both APS and unexplained RPL.  Compared to the controls,  the anti-HSP60 
antibody levels were significantly higher in the APA-positive group of women with unexplained RPL,  and the 
anti-HSP70 antibody levels were significantly higher in APS and APA-positive group of women with unex-
plained RPL.  However,  the anti-HSP60 and anti-HSP70 antibody levels did not correlate with the values of 
baPWV or cAI.  Our results demonstrated anti-HSP60 and anti-HSP70 antibodies are increased in women with 
unexplained RPL.  Further studies are needed to elucidate the roles of anti-HSP antibodies and their pathophys-
iology in unexplained RPL.
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nancy is significantly higher among women with RPL 
compared to healthy controls is indicative of an associ-
ation between the uterine artery blood flow and the 
outcomes of pregnancy [5 , 9].  It is also known that 
women with RPL have higher uterine artery vascular 
resistance even when not pregnant [6 , 10].  We showed 
that the uterine artery pulsatility index (PI) is especially 
high in women with APS [6],  which is diagnosed by 
measuring anti-cardiolipin (CL) antibodies,  lupus anti-
coagulant (LAC) and anti-cardiolipin β2 glycoprotein I 
(CL β2GPI) antibodies [11].  Women with APS are 
known to experience coagulation abnormalities and 
vascular dysfunction [12 , 13].  In addition,  a subset of 
non-pregnant women with unexplained RPL demon-
strate relatively high uterine artery vascular resistance 
[7 , 14],  implying a relationship between vascular dys-
function and pregnancy loss.  Adrenomedullin,  which 
increases in order to compensate for vascular dysfunc-
tion,  is present at higher levels in women with RPL,  
especially in those with APS [6].
An evaluation of arterial stiffness in women with 
RPL by using volume-plethysmography demonstrated 
increased values of brachial-ankle pulse wave velocity 
(baPWV) and the carotid augmentation index (cAI) [8].  
Although increased baPWV values were expected in 
women with APS,  their presence in women with unex-
plained RPL indicates the progression of subclinical 
arteriosclerosis.
Arteriosclerosis including subclinical arterial stiff-
ness and advanced atherosclerosis is a multifactorial 
process [15 ,16],  and its clinical manifestation is thought 
to involve an inflammatory response.  The levels of anti-
heat shock protein (HSP) antibodies are known to be 
elevated in patients with atherosclerosis,  with numer-
ous studies reporting an association of anti-HSP60 and 
anti-HSP70 antibodies in particular with arteriosclero-
sis [17-19].  HSPs are expressed in response to exposure 
to stress factors such as fever,  infection,  and hypoxemia 
[20-22].  HSPs function as molecular chaperones to 
repair degenerated proteins and are present in many 
prokaryotic and eukaryotic species,  and their amino- 
acid sequence and steric structure are highly conserved 
across species [23].
Although HSPs are present in human vascular endo-
thelial cells even under non-stress conditions,  their 
expression on the cell surface increases with exposure to 
stress [16].  Since human HSPs share similarities with 
bacterial HSPs,  they can be recognized as antigens by 
antigen-presenting cells,  resulting in the production of 
anti-HSP antibodies.  The subsequent immune response 
results in failure or the activation of the endothelial 
cells,  causing arteriosclerosis [15-19].
In recent years,  the toxicity of anti-HSP60 and anti-
HSP70 antibodies on vascular endothelial cells was 
confirmed in both in vitro and in vivo studies [24-27],  
suggesting that the presence of anti-HSP60 and anti-
HSP70 antibodies could be correlated with arterioscle-
rosis.  Vascular dysfunction by elevated levels of anti-
HSP60 and anti-HSP70 antibodies may be a novel cause 
of RPL.  Many women with unexplained RPL test posi-
tive for several anti-phospholipid antibodies (APA) 
including anti-phosphatidylethanolamine (PE),  anti- 
phosphatidylserine (PS),  and anti-prothrombin (PT) 
antibodies [28 , 29],  which are not within the APS crite-
ria [11].  However,  the positive ratio of anti-HSP60 and 
anti-HSP70 antibodies in women with RPL,  especially 
those with unexplained RPL,  is not known.
Here we assessed the presence of anti-HSP60 and 
anti-HSP70 antibodies in women with unexplained 
RPL,  and we examined the correlation of these anti-
bodies’ levels with vascular dysfunction.
Materials and Methods
Subjects. Ninety-seven non-pregnant women 
who visited the outpatient clinic of Okayama University 
Hospital between 2006 and 2010 were enrolled in this 
study.  The enrolled women consisted of 68 women with 
a history of loss of 2 or more pregnancies,  forming the 
RPL group,  and 29 healthy women with a normal 
obstetric history and no more than one miscarriage as 
controls.  Women with uterine malformations,  SLE,  
history of smoking,  endocrine disorders such as thyroid 
dysfunction and diabetes,  coagulopathies and chromo-
somal abnormalities in couples were excluded from the 
study.  No subjects had signs of infection when they had 
aborted spontaneously.
The research protocol was approved by the Research 
Ethics Committee of the Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences and Okayama University Hospital (No. 1911,  
1794).  All subjects underwent blood tests,  an ultra-
sound examination and a pulse wave analysis after pro-
viding informed consent.
Biochemical analysis. Blood samples were col-
lected in the morning following overnight fasting 
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during menstruation.  Total cholesterol,  high-density 
lipoprotein (HDL) cholesterol,  low-density lipoprotein 
(LDL) cholesterol,  and triglyceride were analyzed by the 
absorbance measurement method with an automatic 
biochemical analyzer (JCA-BM 2250; JEOL,  Tokyo,  
Japan).  Glucose was measured using a glucose analysis 
apparatus (GA08 III; A&T,  Kanagawa,  Japan).  Insulin 
was measured using a fully automated enzyme immu-
noassay apparatus (AIA-2000; Tosoh,  Tokyo,  Japan).  
Insulin resistance was assessed based on the levels of 
insulin in fasting blood and the homeostasis model 
assessment-R (HOMA-R) index: glucose (mmol/L) ×  
insulin (mIU/L)/22.5 [30].
We used an enzyme-linked immunosorbent assay 
(ELISA) (SRL,  Tokyo,  Japan) to measure the APA lev-
els including anti-CL IgG antibody,  anti-CL IgM anti-
body,  anti-CL β2GPI antibodies,  anti-PE IgG antibody,  
anti-PE IgM antibody,  anti-PS IgG antibody,  anti-PS 
IgM antibody,  and anti-PT antibodies.  We performed 
the dilute Russell viper venom test to analyze the levels 
of LAC (BML,  Tokyo,  Japan).  The measurements of 
anti-CL IgG antibody,  anti-CL IgM antibody,  LAC,  
and anti-CL β2GPI antibodies were conducted twice 
with a minimum interval of 12 weeks.  APS was diag-
nosed by using the Sapporo criteria [11].  Anti-HSP60 
and anti-HSP70 antibodies were measured by using 
their respective ELISA kits (EKS-650,  EKS-750; Enzo 
Life Sciences,  Farmingdale,  NY,  USA) at a serum dilu-
tion of 1 : 1000.
Evaluation of arterial stiffness. We assessed arte-
rial stiffness with a pulse wave analysis by using a vol-
ume-plethysmographic apparatus (Form/ABI,  Omron 
Colin,  Tokyo,  Japan) [31-33].  The measurements were 
made with the subject in a supine position after a 5-min 
rest.  A blood pressure cuff was applied on each upper 
arm and each ankle,  and electrocardiogram (ECG) 
leads were applied to each wrist.  A microphone was 
placed on the left edge of the rib to facilitate the collec-
tion of cardiac sounds.  The ECG and phonocardiogram 
measurements were taken simultaneously,  along with 
the blood pressure measurement from the 4 limbs.
The ankle-brachial index (ABI) is expressed as the 
ratio of the maximum blood pressures measured at the 
ankles and the upper arms.  An ABI < 1.0 in either leg 
was considered abnormal,  suggesting peripheral arte-
rial disease; progressively lower ABI values were con-
sidered to indicate more severe obstruction.  Arterio-
sclerosis obliterans (ASO) was defined as an ABI ≤ 0.9.
The baPWV was used as a substitute for aortic PWV,  
as there is a strong correlation between the two.  Since 
the baPWV of the upper right arm correlated strongly 
with the baPWV of the left arm (r = 0.96,  p < 0.0001),  
we used the right arm baPWV values for the subsequent 
analysis.
The cAI was measured by placing a multi-element 
applanation tonometry sensor on the common carotid 
artery and calculated based on the central artery wave-
form impacted by the reflected wave from the periph-
eral artery.  Pulse waves over a 30-sec period were 
recorded and stored.  The validity and reliability of this 
tonometry sensor have been reported [34].
Pulsed Doppler ultrasonography of the uterine 
arteries. The uterine artery PI was measured during 
the midluteal phase of the menstrual cycle with a 5.0-
MHz transvaginal probe (SSD-3500®,  Aloka,  Tokyo,  
Japan) [5 , 7].
Statistical analyses. The Mann-Whitney U-test 
was used to compare differences between the groups.  
The Pearson product-moment correlation coefficient 
was used to examine the correlations between the dif-
ferent variables.  All analyses were performed using the 
software package IBM SPSS Statistics,  ver. 20.  Signifi-
cance was set at p < 0.05.
Results
Clinical features and laboratory data. Fourteen 
subjects with RPL were diagnosed as having APS by 
using the Sapporo criteria (Table 1).  Fifty-four subjects 
did not satisfy the Sapporo criteria and were classified as 
having unexplained RPL.  Among the 54 women with 
unexplained RPL,  32 tested positive for at least one 
APA including anti-CL antibodies (immunoglobulins G 
and/or M),  LAC,  anti-CL β2GPI antibodies,  anti-PE 
antibodies (immunoglobulins G and/or M),  anti-PS 
antibodies (immunoglobulins G and/or M),  and/or 
anti-PT antibodies.  The remaining 22 subjects tested 
negative for all of these APAs.
We divided the entire RPL group into the APS group 
and the unexplained RPL group.  The unexplained RPL 
group was further divided into the APA-positive group 
and the APA-negative group.  There were no significant 
differences in age,  height,  body weight,  or body mass 
index (BMI) among the different groups.
The subjects’ total cholesterol,  HDL cholesterol,  
LDL cholesterol,  triglycerides,  glucose,  and insulin 
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levels in fasting blood samples were all within the nor-
mal range.  There were no significant differences in these 
values among the groups.
Arterial stiffness. None of the subjects were 
found to have high blood pressure values (Table 2).  
While systolic blood pressure was higher in the APS 
group compared to the control group,  diastolic blood 
pressure was not significantly different among the 
groups.  The ABI,  which we used as an index of arterial 
occlusion,  was not significantly different among the 
groups.  However,  baPWV,  which we used as an indi-
cator of arterial stiffness,  was significantly higher in the 
women with RPL compared to the control group.  In 
addition,  all of the subgroups of women with RPL had 
significantly higher values of baPWV compared to the 
control group.
The cAI,  which we used as another index of arterial 
stiffness,  was significantly higher in the women with 
RPL compared to the control group.  In addition,  all of 
the subgroups of women with RPL had significantly 
higher cAI values compared to the control group.  
Similarly,  the uterine artery PI values were also signifi-
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Table 2　 Arterial stiﬀness evaluated by volume-plethysmography and endovaginal ultrasonography
RPL
Unexplained
Control
(n＝29)
Total
(n＝68)
APS
(n＝14)
Total
(n＝54)
APA positive
(n＝32)
APA negative
(n＝22)
Systolic BP (mmHg) 106.1±7.4 109.8±9.1 113.5±9.8＊ 108.8±8.8 110.2±9.5 106.8±7.5
Diastolic BP (mmHg) 63.8±7.3 66.8±7.7 67.9±8.9 66.5±7.4 67.7±8.2 64.7±5.9
ABI 1.05±0.06 1.07±0.07 1.05±0.07 1.07±0.08 1.06±0.08 1.09±0.06
baPWV (cm/sec) 1,075±102 1,170±117＊＊ 1,220±160＊＊ 1,157±103＊＊ 1,159±113＊＊ 1,154±87.4＊
cAI (%) －7.8±13.8 3.6±14.2＊＊ 1.8±12.1＊ 4.1±14.8＊＊ 1.6±14.6＊＊ 7.8±14.6＊＊
Uterine artery PI 2.30±0.33 3.07±1.1＊＊ 3.21±1.2＊ 2.99±1.1＊ 2.87±0.9＊ 3.20±1.4＊
Values are expressed as mean ± S.D. Statistically signiﬁcant when compared to the control group,  ＊p＜0.05,  ＊＊p＜0.01.
RPL,  recurrent pregnancy loss; APS,  anti-phospholipid syndrome; APA,  anti-phospholipid antibody; BP,  blood pressure; ABI,  ankle-bra-
chial index; baPWV, brachial-ankle pulse wave velocity; cAI,  carotid augmentation index; PI,  pulsatility index.
Table 1　 Clinical features and Laboratory data of the study subjects
RPL
Unexplained
Control
(n＝29)
Total
(n＝68)
APS
(n＝14)
Total
(n＝54)
APA positive
(n＝32)
APA negative
(n＝22)
Age (Years) 30.6±7.5 33.7±4.6 33.8±5.5 33.7±4.4 33.4±4.5 34.2±4.4
Pregnancy loss 0 [0-1] 3 [2-5] 4 [2-5] 3 [2-5] 2 [2-5] 3 [2-5]
Height (cm) 158.3±5.1 156.8±4.9 157.4±6.9 156.7±4.4 157.1±4.4 156.0±4.4
Body weight (kg) 55.2±9.6 52.4±5.3 53.9±5.2 52.0±5.3 52.7±5.1 50.9±5.4
BMI (kg/m2) 21.9±3.4 21.3±2.4 21.9±2.8 21.2±2.3 21.4±2.2 21.0±2.5
Total cholesterol (mg/dL) 196.1±32.9 189.3±27.7 193.8±38.2 188.1±24.5 184.7±22.2 192.9±27.3
HDL-C (mg/dL) 71.4±16.3 70.4±13.3 70.2±17.7 70.5±12.3 69.8±11.7 71.4±13.3
LDL-C (mg/dL) 109.5±29.5 105.7±24.6 108.9±36.6 105.0±21.3 103.1±20.9 107.5±22.0
Triglycerides (mg/dL) 60.9±27.1 65.6±32.0 82.4±51.4 61.8±24.8 61.1±21.9 62.6±28.8
Glucose (mg/dL) 90.5±8.2 90.1±6.1 88.4±7.6 90.6±5.6 91.4±5.8 89.4±5.1
Insulin (μU/ml) 4.5±2.1 4.7±2.5 5.4±3.3 4.6±2.3 4.7±2.7 4.4±1.6
HOMA-R 1.0±0.5 1.1±0.6 1.3±0.8 1.1±0.6 1.2±0.8 0.9±0.4
Values are expressed as mean ± S.D or median [range].
RPL,  recurrent pregnancy loss; APS,  anti-phospholipid syndrome; APA,  anti-phospholipid antibody; BMI,  body mass index; HDL-C,  high 
density lipoprotein-cholesterol; LDL-C,  low density lipoprotein-cholesterol; HOMA-R,  homeostatic model analysis ratio.
cantly higher in all of the subgroups of women with RPL 
compared to the control group.
Anti-HSP antibodies. The anti-HSP60 antibody 
levels in the APS group were not significantly different 
from the levels in the control group (Fig. 1).  These lev-
els were significantly higher in the entire unexplained 
RPL group compared to the control group.  Among the 
subgroups in the unexplained RPL group,  the APA-
positive group had higher anti-HSP60 antibody levels 
compared to the control group,  whereas the APA-
negative group did not show any significant difference 
in anti-HSP60 antibody levels.
The anti-HSP70 antibody levels were significantly 
higher in the APS group as well as in the unexplained 
RPL group compared to the control group (Fig. 2).  
Among the subgroups in the unexplained RPL group,  
the APA-positive group had higher anti-HSP70 anti-
body levels compared to the control group,  whereas the 
APA-negative group did not show any significant differ-
ence in these levels.
We analyzed the correlations between the levels of 
the different antibodies and the various indices of arte-
rial stiffness.  There was no significant correlation 
between anti-PE antibodies,  anti-PS antibodies or 
anti-PT antibodies and the baPWV values or the cAI 
values.  There was also no significant correlation between 
the anti-HSP60 antibody levels and the baPWV values 
or the cAI values (Fig. 3A , B).  Similarly,  there was no 
significant correlation between the anti-HSP70 antibody 
levels and the baPWV values or the cAI values (Fig. 3C,  
D).  No correlation was observed regardless of whether 
the group analyzed was the entire RPL group or the 
unexplained RPL group (data not shown).
Discussion
In the present study,  the women with unexplained 
RPL showed high uterine artery resistance and 
increased systemic arterial stiffness despite their youth 
and the absence of blood pressure or cholesterol eleva-
tion.  These results are similar to our earlier findings [8].  
In the unexplained RPL group,  increased values of 
baPWV and cAI were observed as well as APS,  which 
involves arteriosclerosis.
A baPWV of 1,400 cm/sec is equivalent to interme-
diate risk on the Framingham risk score [35],  with a 
10-20% predicted risk of severe coronary artery disease 
over the next 10 years.  In the present study,  the mean 
baPWV value for the women with RPL was 1,170 cm/
sec.  However,  4.4% of these women (mean age,  39.0 
years) had baPWV values of 1,400 cm/sec or higher.  
Since improvements in baPWV values are known to 
result from weight loss,  smoking cessation,  use of anti-
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Fig. 2　 Anti-HSP70 antibody levels.  Bars＝ the medians.
hypertensive drugs and oral hypoglycemic agents,  life-
style interventions such as exercise and proper diet 
would help prevent severe coronary artery disease.
The present study is the first to demonstrate higher 
levels of anti-HSP60 and anti-HSP70 antibodies among 
the portion of women with unexplained RPL.  Although 
the levels of anti-HSP60 and anti-HSP70 antibodies 
were significantly higher in the women with unex-
plained RPL,  the APA-positive group was the main 
contributor to the significant elevation of these antibod-
ies.  In the APA-positive group,  in which women tested 
positive for anti-PE,  anti-PS,  and/or anti-PT antibodies 
of unknown significance in RPL,  anti-HSP60 and anti-
HSP70 autoantibodies may be produced under patho-
logical conditions similar to autoimmune disorders that 
are not part of the definitive diagnosis of APS.
An in vivo experiment involving mice suggested that 
anti-HSP60 antibodies may contribute to vascular 
endothelial cell toxicity [24].  In addition,  anti-HSP60 
antibody adherence to normal vascular endothelial cells 
may result in the cells’ apoptosis [25].  Another study 
reported the development of aortic atherosclerosis in 
rats following intravenous injections of anti-HSP70 
antibody administered through peripheral vessels [26].  
Thus,  there is evidence to suggest that increased levels 
of anti-HSP60 and anti-HSP70 antibodies are associated 
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with arteriosclerosis.  In the present study,  however,  
baPWV and cAI did not correlate with the anti-HSP60 
and anti-HSP70 antibody levels in the women with RPL 
and also in the control group.
For the evaluation of an individual’s vascular condi-
tion,  there are various parameters other than the 
baPWV and cAI such as flow-mediated vasodilation 
(FMVD) and carotid artery intima-media thickness 
(cIMT).  A study that examined the relationship between 
cIMT and anti-HSP antibody reported their positive 
correlation in healthy individuals [36],  but this was a 
state in which arterial sclerosis had been somewhat 
advanced.  We have found no report examining the rela-
tionships between anti-HSP antibody and the baPWV,  
the cAI and FMVD,  which may reflect early-stage vas-
cular dysfunction.  The negative impact of anti-HSP 
antibody on the blood vessels of women with RPL 
should be monitored over a long term.
It is possible that high levels of anti-HSP60 and anti-
HSP70 antibodies,  as seen in women with unexplained 
RPL,  may contribute to miscarriage or stillbirth by a 
mechanism other than vascular dysfunction.  HSPs,  
which are normally present in the placenta of healthy 
individuals,  increase in response to various factors such 
as oxidative stress,  infection and ischemia,  as a tissue- 
protective mechanism.  It has been demonstrated that 
exposing the chorionic villi of rats to ultrasound for 10 
and 20 min resulted in an increase in the expression of 
HSP70 and the inhibition of apoptosis,  which in turn 
was associated with the suppression of tissue damage 
[37],  indicating the placental tissue-protective effect of 
HSP70.
In addition,  the tissue-protective effect of HSP was 
similarly observed in colonic and oral mucosa [38 , 39].  
The expression of HSP70 was significantly higher in the 
chorionic villi of women who spontaneously aborted at 
8-13 weeks of gestation compared to women with nor-
mal pregnancies at the corresponding gestational week 
[40].  Similarly,  the placentas of women presenting with 
intrauterine fetal growth restriction also showed higher 
expressions of HSP27 , 60 , 70,  and 90 in the synctiotro-
phoblasts and cytotrophoblasts of avascular villi and villi 
with thrombi compared to a full-term control group 
[41].  Anti-HSP antibodies may prevent the ability of 
HSPs to effectively protect tissues in response to stress.
In addition,  in vitro studies have confirmed the 
direct cytotoxicity of anti-HSP70 antibody against tis-
sues that express HSP70 [27].  The presence of anti-
HSP60 and anti-HSP70 antibodies prior to pregnancy 
may result in direct placental damage if the chorionic 
cells express a higher antigenic load of HSP60 and 
HSP70,  as is seen with a stressed placenta.  This could 
be another mechanism of anti-HSP antibodies resulting 
in adverse outcomes of pregnancy,  especially in unex-
plained RPL.
Additionally,  in the present study’s APA-negative 
group with relatively low levels of anti-HSP activity,  
arteriosclerosis was also observed even though women 
in the group were not considered to have autoimmune 
disorders.  The causes of arteriosclerosis in the APA-
negative group are not yet clear.  Other factors such as 
subclinical infection and vascular abnormality may 
affect arterial conditions resulting in pregnancy loss.  
However,  along with significantly elevated uterine 
artery resistance,  an unexplained cause of arterial dis-
order might trigger impaired uterine perfusion,  result-
ing in RPL.  Further detailed examinations of APA-
negative women with RPL may shed light on the causes 
of unexplained RPL.
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